Connect with us

Hi, what are you looking for?

Investing

BridgeBio Pharma Shares Rise 14% on Expected Results from Heart-Disease Study

By Sabela Ojea


Shares of BridgeBio Pharma climbed 14% to $20.85 in after-hours Friday trading after the company said it would share results from the latest phase of its transthyretin amyloid cardiomyopathy heart disease study.

The commercial-stage biopharmaceutical company is set to make public findings from the phase 3 ATTRibute-CM clinical study during an investor call on Monday.

Transthyretin amyloid cardiomyopathy is a rare cause of restrictive cardiomyopathy.


Write to Sabela Ojea at [email protected]


Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Uncategorized

Blogs The fresh detachment procedure in the SlotoCash Local casino usually requires the following procedures: – 50 free spins on Rapid Reels no deposit...

News

This feature is available for all the players and this feature will make the whole gaming experience exciting and unforgettable for the players. This...

News

With other methods of payment, the cost of the conversion is passed onto the player and any winnings generated from that method are converted...

News

If, however, you’re using an alternative banking method, you can click on the ‘Go to Alternative banking’ link to be directed to the page...